Re: Secondary bacterial pneumonia A private company is trying to outdo PFE and MRK in the very large market for vaccines against pneumococcal pneumonia, which has become even more relevant during the COVID-19 outbreak: https://endpts.com/sutrovax-lands-another-100m-in-upstart-quest-against-pfizers-blockbuster-prevnar-13/ See #msg-154439687 for related info.